Dailypharm Live Search Close

Pharmbio's Orafang was published in the JCC

By Nho, Byung Chul | translator Choi HeeYoung

22.07.12 09:40:06

°¡³ª´Ù¶ó 0
Comparative clinical trials with 2L PEGs for IBD patients



Pharmbio (Chairman Nam Bong-gil) announced on the 12th that the comparative clinical results on the use of Orafang PO and 2L PEG drugs for IBD patients in Ccaid were introduced in the famous journal Journal of Cron's and Colitis.

JCC is an SCIE-class medical journal in the field of inflammatory bowel disease published by Oxford University Press (OUP), and is a prestigious paper with an impact index of 9.485 over the past five years. In the paper, the comparative clinical results of the intestinal crystallinity (HCS) of the two preparations revealed that the intestinal tract of Orafang was significantly excellent in all compartments such as ascending colon (3.06<3.38), transverse colon (3.25<3.62), desce

Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)